244 / 260
(
`
cr)
Particulars
Life Science
Chemicals
Performance and
Other Chemicals
Others
Total
2018-19
2017-18
2018-19
2017-18
2018-19
2017-18
2018-19
2017-18
iii) Other information
Segment assets
856.52
723.78 1,708.02 1,591.20
60.16
73.59
ǨȡǬǨǪȦǭǦ
2,388.57
ÀŠîŕŕūČîƥĚē ČūŞŞūŠ îƙƙĚƥƙ
919.27
625.02
Total assets
ǩȡǫǪǩȦǯǭ
3,013.59
Segment liabilities
ǧǯǭȦǧǪ ǧǪǯȦǨǧ ǩǬǪȦǮǭ
395.50
9.50
18.98
571.51
563.69
ÀŠîŕŕūČîƥĚē ČūŞŞūŠ
liabilities
ǨǪǨȦǯǫ
185.97
Total liabilities
ǮǧǪȦǪǬ ǭǪǯȦǬǬ
Additions to assets and
intangible assets
81.05
ǪǦȦǮǯ
153.83
ǯǬȦǪǩ
ǯȦǮǪ
ǧȦǨǪ ǨǪǪȦǭǨ
138.56
ÀŠîŕŕūČîƥĚē îēēĿƥĿūŠƙ ƥū
assets and intangible assets
0.68
2.31
¹ūƥîŕ ČîƎĿƥîŕ ĚNJƎĚŠēĿƥƭƑĚȜ
ǨǪǫȦǪǦ ǧǪǦȦǮǭ
Depreciation
ǩǨȦǪǫ
31.29
ǮǧȦǭǪ
73.93
1.68
2.38
115.87
107.60
ÀŠîŕŕūČîƥĚē ēĚƎƑĚČĿîƥĿūŠ
ǩȦǦǪ
2.78
Total depreciation
118.91
110. 38
c) Secondary segment - geographical
(
`
cr)
Particulars
In India
Outside India
Total
2018-19
2017-18
2018-19
2017-18
2018-19
2017-18
Segment revenue
1,978.13 1,630.60 2,059.68 1,707.32
ǪȡǦǩǭȦǮǧ
3,337.92
Carrying cost of assets by location of assets
3,225.26
ǨȡǭǪǮȦǭǪ
318.71
ǨǬǪȦǮǫ ǩȡǫǪǩȦǯǭ
3,013.59
Additions to assets and intangible assets*
ǨǪǫȦǪǦ ǧǪǦȦǮǭ
-
-
ǨǪǫȦǪǦ ǧǪǦȦǮǭ
Other disclosures:
Ŀȴ
¹ĺĚ HƑūƭƎ ĺîƙ ēĿƙČŕūƙĚē ċƭƙĿŠĚƙƙ ƙĚijŞĚŠƥ îƙ ƥĺĚ ƎƑĿŞîƑNj ƙĚijŞĚŠƥ DžĺĿČĺ ĺîDŽĚ ċĚĚŠ ĿēĚŠƥĿǛĚē ĿŠ ŕĿŠĚ DžĿƥĺ ƥĺĚ TŠē ¬ ǧǦǮ
‘Operating Segments’ taking into account the organisation structure as well as the differing risks and returns.
ĿĿȴ ¹ĺĚ ƙĚijŞĚŠƥ ƑĚDŽĚŠƭĚȡ ƑĚƙƭŕƥƙȡ îƙƙĚƥƙ îŠē ŕĿîċĿŕĿƥĿĚƙ ĿŠČŕƭēĚ ƑĚƙƎĚČƥĿDŽĚ îŞūƭŠƥƙ ĿēĚŠƥĿǛîċŕĚ ƥū ĚîČĺ ƙĚijŞĚŠƥ îŠē îŞūƭŠƥƙ
allocated on a reasonable basis.
iii) The Group accounts for inter segment sales and transfers at market price.
*Including capital work-in-progress and capital advances
Note 29.16 Business Combination
a) Brief of the transaction
During the year, a subsidiary company acquired manufacturing facilities of Polydrug Laboratories Pvt Ltd based at
Ambernath additional MIDC through slump sale as a continuing business effective, January 01, 2019. The transaction
has been entered by a subsidiary company to move ahead in value chain from Active Pharmaceutical Ingredient (API)
Intermediates manufacturer to an API manufacturer.
Note 29.15 Segment information (continued)
ǨǪǨ
Atul Ltd | Annual Report 2018-19
Corporate Overview 01-22
Statutory Reports 23-105
Financial Statements 107-250